Produced by 
MAY 02, 2016 08:00 AM PDT
Evolving Practice: Role of Anti-Factor Xa Testing in Modern Anticoagulation
Presented at the Stago EdVantage Virtual University Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
1 1 254

Speakers:
  • Clinical Assistant Professor of Pharmacy Practice, University of Wyoming School of Pharmacy
    Biography
      Dr. Vandiver joined the University of Wyoming School of Pharmacy in July 2012 as a Clinical Assistant Professor of Pharmacy Practice. Upon graduating from the University of Colorado Health Sciences Center with a Doctor of Pharmacy in 2010, he completed a PGY1 pharmacy practice residency at Exempla Saint Joseph Hospital, located in Denver, Colorado. Dr. Vandiver then went on to complete a PGY2 internal medicine specialty residency, also at Exempla Saint Joseph Hospital. He is a Board Certified Pharmacotherapy Specialist. His current practice site is at Swedish Medical Center in Englewood, Colorado, practicing as an inpatient clinical pharmacist with the Swedish Family Medicine Residency Program. His academic interests include anticoagulation, pain management, cardiology, and transitions of care. Dr. Vandiver offers internal medicine rotations at Swedish Medical Center.

    Abstract:
    Laboratory monitoring of oral and parenteral anticoagulants plays a key role in ensuring their safe and effective use.  Laboratory personnel play an essential role in ensuring appropriate use and interpretation of these lab tests. This webinar will focus on the monitoring of unfractionated heparin and the newer direct oral anticoagulants, focusing on anti-factor Xa testing.
    • Describe the advantages and disadvantages of using the activated partial thromboplastin time (aPTT) versus an anti-factor Xa assay to monitor the effects of unfractionated heparin.
    • Recommend appropriate laboratory testing to assess coagulation status in patients taking a direct oral anticoagulant (DOAC).
    • Discuss the role of anti-factor Xa assays in monitoring oral and parenteral anticoagulants.

    Show Resources
    Show Resources